Fast Five Quiz: Metastatic Melanoma Treatment

Winston W. Tan, MD, FACP


May 24, 2023

European Society for Medical Oncology (ESMO) guidelines recommend that for patients with metastatic melanoma with BRAF mutations and elevated LDH, combination therapy with ipilimumab plus nivolumab is preferred over BRAF/MEK inhibitors in the first line, though other adverse prognostic factors may also be relevant. In general, the presence of the BRAF mutation, harbored by approximately half of the melanomas, may be used to guide treatment decisions in advanced melanoma.

In addition, elevated serum LDH is a prognostic factor in patients with stage IV melanoma and is linked to greater tumor burden. A subset of patients with normal LDH levels and a lower number of organ sites who were treated with targeted combination therapy with dabrafenib and trametinib experienced durable outcomes.

Learn more about the treatment of advanced-stage melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.